A
Amanda Olson
Researcher at University of Texas MD Anderson Cancer Center
Publications - 102
Citations - 1372
Amanda Olson is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 16, co-authored 83 publications receiving 945 citations.
Papers
More filters
Journal ArticleDOI
Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation.
Uday R. Popat,Rohtesh S. Mehta,Katy Rezvani,Patricia S. Fox,Kayo Kondo,David Marin,Ian McNiece,Betul Oran,Chitra Hosing,Amanda Olson,Simrit Parmar,Nina Shah,Michael Andreeff,Partow Kebriaei,Indreshpal Kaur,Eric Yvon,Marcos de Lima,Laurence J.N. Cooper,Priti Tewari,Richard E. Champlin,Yago Nieto,Borje S. Andersson,Amin M. Alousi,Roy B. Jones,Muzaffar H. Qazilbash,Qaiser Bashir,Stefan O. Ciurea,Sairah Ahmed,Paolo Anderlini,Doyle Bosque,Catherine M. Bollard,Jeffrey J. Molldrem,Julianne Chen,Gabriela Rondon,Mike Thomas,Leonard D. Miller,Steve Wolpe,Paul J. Simmons,Simon P. Robinson,Patrick A. Zweidler-McKay,Elizabeth J. Shpall +40 more
TL;DR: Findings support ex vivo fucosylation of multipotent CD34(+) CB cells as a clinically feasible means to improve engraftment efficiency in the double CBT setting.
Journal ArticleDOI
Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy.
Muharrem Muftuoglu,Amanda Olson,David Marin,Sairah Ahmed,Victor E. Mulanovich,Sudhakar Tummala,T. Linda Chi,Alessandra Ferrajoli,Indreshpal Kaur,Li Li,Richard E. Champlin,Elizabeth J. Shpall,Katayoun Rezvani +12 more
TL;DR: Three immunosuppressed patients with PML were treated with ex vivo–expanded, partially HLA‐matched, third‐party–produced, cryopreserved BK virus–specific T cells with T‐cell infusion, finding alleviation of the clinical signs and imaging features of PML and JC virus in the cerebrospinal fluid cleared.
Journal ArticleDOI
Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies
Juliet N. Barker,Joanne Kurtzberg,Karen K. Ballen,Michael Boo,Claudio G. Brunstein,Corey Cutler,Mitchell E. Horwitz,Filippo Milano,Amanda Olson,Stephen R. Spellman,John E. Wagner,Colleen Delaney,Elizabeth J. Shpall +12 more
TL;DR: A practical "how to" guide to CBT for hematologic malignancies on behalf of the National Marrow Donor Program and the American Society of Blood and Marrow Transplantation's Cord Blood Special Interest Group is provided.
Journal ArticleDOI
IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation
Anushruti Sarvaria,Rafet Basar,Rohtesh S. Mehta,Hila Shaim,Muharrem Muftuoglu,Ahmad Khoder,Takuye Sekine,Elif Gokdemir,Kayo Kondo,David Marin,May Daher,Amin M. Alousi,Abdullah Alsuliman,Enli Liu,Betul Oran,Amanda Olson,Roy B. Jones,Uday R. Popat,Chitra Hosing,Richard E. Champlin,Elizabeth J. Shpall,Katayoun Rezvani +21 more
TL;DR: It is demonstrated that CB contains an abundance of B cells with immunoregulatory function and the suppressive capacity of CB-derived Bregs can be potentiated through CD40L signaling, suggesting that inflammatory environments may induce their function.
Journal Article
The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo.
Joann P. Palma,Luis E. Rodriguez,Velitchka Bontcheva-Diaz,Jennifer J. Bouska,Gail Bukofzer,Milagros Colon-Lopez,Ran Guan,Kenneth Jarvis,Eric F. Johnson,Vered Klinghofer,Xuesong Liu,Amanda Olson,Mary Saltarelli,Yan Shi,Jason Stavropoulos,Gui-Dong Zhu,Thomas D. Penning,Yan Luo,Vincent L. Giranda,Saul H. Rosenberg,David Frost,Cherrie K. Donawho +21 more
TL;DR: Potentiation of TMZ activity by ABT-888 correlated with drug levels and inhibition of PARP activity in vivo, and is in Phase 1 trials using a validated ELISA based on the assay developed here to assess pharmacological effect.